Tirzepatide vs Liraglutide
Both Tirzepatide and Liraglutide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.
Tirzepatide
Evidence A+Tirzepatide (Mounjaro / Zepbound)
A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.
View full Tirzepatide profile →Liraglutide
Evidence A+Liraglutide (Saxenda / Victoza)
The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.
View full Liraglutide profile →Side-by-Side
| Attribute | Tirzepatide | Liraglutide |
|---|---|---|
| Evidence Grade | A+ | A+ |
| FDA Status | FDA-approved for weight management and type 2 diabetes | FDA-approved for weight management (Saxenda) and type 2 diabetes (Victoza) |
| Typical Dose | 2.5–15 mg weekly (subcutaneous injection) | 0.6–3.0 mg daily (subcutaneous) |
| Clinics Indexed | 1,850 | 540 |
| Categories | weight-loss, metabolic | weight-loss, metabolic |
Key reported benefits — Tirzepatide
- ✓Superior weight loss
- ✓Dual hormone targeting
- ✓Blood sugar control
- ✓Reduced cardiovascular risk
Key reported benefits — Liraglutide
- ✓Weight loss
- ✓Appetite suppression
- ✓Glycemic control
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.